- |||||||||| bortezomib / Generic mfg., prednisone / Generic mfg., bendamustine / Generic mfg.
Enrollment closed: Bendamustine, Bortezomib (Velcade (clinicaltrials.gov) - Apr 9, 2015 P2, N=60, Active, not recruiting, N=100 --> 120 | Trial primary completion date: Apr 2015 --> Mar 2016 Recruiting --> Active, not recruiting
- |||||||||| Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe
Trial completion, Phase classification, Enrollment change: Viral Kinetics in HCV Clearance in Subjects With Hemophilia (clinicaltrials.gov) - Apr 6, 2015 P1, N=5, Completed, N=60 --> 0 Active, not recruiting --> Completed | Phase classification: P4 --> P1 | N=20 --> 5
- |||||||||| melphalan / Generic mfg., lenalidomide / Generic mfg.
Trial completion, Trial primary completion date: Lenalidomide and High-Dose Melphalan (clinicaltrials.gov) - Mar 31, 2015 P1/2, N=61, Completed, Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Mar 2016 --> Mar 2015
- |||||||||| VLX1570 / Vivolux
Enrollment open: A Study of VLX1570 and Dexamethasone in Myeloma Patients (clinicaltrials.gov) - Mar 31, 2015 P1/2, N=65, Recruiting, Active, not recruiting --> Completed | Trial primary completion date: Mar 2016 --> Mar 2015 Not yet recruiting --> Recruiting
- |||||||||| Trial completion, Enrollment change, HEOR: Quality of Life Study of Helixate NexGen (clinicaltrials.gov) - Mar 20, 2015
P=N/A, N=78, Completed, Not yet recruiting --> Recruiting Active, not recruiting --> Completed | N=150 --> 78
- |||||||||| Fragmin (dalteparin sodium) / Pfizer, Eisai
Enrollment closed, Combination therapy: Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma (clinicaltrials.gov) - Mar 10, 2015 P2, N=30, Active, not recruiting, Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
|